Cambridge Scientists Solve GIPR Paradox: Distinct Brain Circuits Explain Why Both Activating and Blocking the Same Receptor Drives Weight Loss
核心洞察
GIPR (搜索) agonists suppress appetite by directly stimulating receptors in the brainstem area postrema, while GIPR antagonists promote weight loss by blocking receptors in the hypothalamus.
Blocking GIPR (搜索) in the hypothalamus removes an inhibitory "brake" that normally limits the brainstem's sensitivity to satiety signals, enhancing GLP-1 drug efficacy.
GIPR (搜索) antagonism also sensitizes the brain to amylin receptor agonists like cagrilintide, opening new avenues for combination obesity (搜索) therapeutics.
Cambridge scientists have resolved a long-standing puzzle in obesity (搜索) pharmacology: why both stimulating and blocking the same brain receptor—the glucose-dependent insulinotropic polypeptide receptor (GIPR (搜索))—can lead to meaningful weight loss. Published in Nature Metabolism, the study demonstrates that the answer lies in anatomically distinct brain circuits, with GIPR agonists and antagonists operating through entirely different regions to achieve their therapeutic effects.
The research, led by investigators at the University of Cambridge's Institute of Metabolic Science, used genetically engineered mouse models with cell-type and region-specific knockout of GIPR (搜索) to isolate the contributions of the brainstem and hypothalamus. Their findings not only explain the clinical success of existing dual-action therapies but also chart a rational path toward next-generation combination obesity (搜索) treatments.
Two Brain Regions, Two Mechanisms
The team generated mice lacking GIPR (搜索) specifically in either the area postrema (AP) of the brainstem—a region involved in appetite and nausea that lies outside the blood–brain barrier—or the hypothalamus, a major center controlling hunger and body weight. Control mice received injections of a GFP-encoding virus.
When treated with acyl-GIP, a long-acting GIPR (搜索) agonist, control mice showed the expected reductions in food intake and body weight. However, mice lacking GIPR in the area postrema (Gipr^AP-KO) completely lost this response. "Gipr^AP-KO mice exhibit reduced responsiveness to the appetite-suppressing effects of acyl-GIP," the authors report. In both lean and diet-induced obese (DIO) mice, acyl-GIP failed to reduce food intake when GIPR was absent from the AP, confirming that GIPR agonism requires this brainstem population to suppress appetite.
Conversely, mice lacking GIPR (搜索) in the hypothalamus (Gipr^hypo-KO) retained normal appetite suppression from acyl-GIP but showed enhanced weight loss when treated with the GLP-1 receptor agonist liraglutide. Critically, adding a GIPR antagonist peptide to liraglutide produced additional weight loss in control mice, but this synergistic effect was abolished in Gipr^hypo-KO animals—demonstrating that GIPR antagonists exert their effects through hypothalamic receptors.
Releasing the Hypothalamic Brake
The study reveals that GIPR (搜索) in the hypothalamus acts as an inhibitory "brake" that normally constrains the brainstem's capacity to process satiety signals. By blocking GIPR in the hypothalamus, GIPR antagonists effectively release this brake, sensitizing the brain to multiple classes of satiety-inducing drugs.
This mechanism explains why combining GIPR (搜索) antagonism with GLP-1 receptor agonism produces greater weight loss than GLP-1 agonism alone. The researchers demonstrated this directly: liraglutide plus a GIPR antagonist peptide induced significantly more weight loss and food intake suppression than liraglutide monotherapy in control mice, an effect that disappeared when hypothalamic GIPR was absent.
Synergy Beyond GLP-1: Amylin Receptor Sensitization
In a finding with significant therapeutic implications, the team showed that GIPR (搜索) antagonism also sensitizes the brain to cagrilintide, a long-acting amylin analogue that targets amylin receptors in the hindbrain. Wild-type mice treated with the combination of cagrilintide and a GIPR antagonist achieved greater weight loss than either agent alone. Furthermore, Gipr^hypo-KO mice treated with cagrilintide alone exhibited sustained weight loss superior to that seen in wild-type animals.
"GIPR (搜索) antagonism and Gipr^hypo-KO also sensitise to cagrilintide-induced weight loss," the authors note, suggesting that GIPR blockade could potentially strengthen several types of anti-obesity (搜索) medicines beyond GLP-1-based therapies.
Clinical Implications and the Pipeline
The findings provide a mechanistic foundation for understanding the clinical performance of major obesity (搜索) therapeutics. Tirzepatide (Mounjaro/Zepbound), a dual GIPR (搜索)/GLP-1 receptor agonist, and MariTide, a bispecific molecule combining GIPR antagonism with GLP-1 receptor agonism currently in phase 3 clinical trials, both produce substantial weight loss despite their opposite actions at GIPR.
Dr. Jo Lewis, the study's first author, explained: "Understanding which brain circuits respond to these medications—and how they do so—could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity (搜索) medicines to even greater effect."
The research also tested whether GIPR (搜索) antagonism requires central GLP-1 production by ablating preproglucagon (Ppg) neurons in the nucleus tractus solitarius. The results showed that Ppg neuron ablation did not attenuate the effects of any treatment arm, indicating that GIPR antagonism does not depend on central GLP-1.
"Our work also strengthens the idea that the brain is central to obesity (搜索) treatment," Lewis added. "Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake."
With more than one billion people worldwide living with obesity (搜索)—a condition that increases the risk of type 2 diabetes (搜索), cardiovascular disease, and cancer—these insights into the neural circuitry of weight regulation offer a rational framework for designing the next generation of combination therapies, including emerging multi-incretin candidates like CagriSema.